CD4 (+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L: CD154) antibody lose their graft-versus-host disease lethality capacity but retain …
BR Blazar, PA Taylor, RJ Noelle… - The Journal of clinical …, 1998 - Am Soc Clin Investig
BR Blazar, PA Taylor, RJ Noelle, DA Vallera
The Journal of clinical investigation, 1998•Am Soc Clin InvestigA major goal of the transplant field is to tolerize donor T cells to prevent graft-versus-host
disease (GVHD)(1). We describe an ex vivo approach in which the blockade of CD40 ligand
(CD40L: CD154): CD40 interactions, a pathway required for optimal T cell expansion,
induces donor CD4 (+) T cells to become tolerant to host alloantigens (2). High doses of
tolerized cells did not cause GVHD lethality in vivo. T cells had intact responses to antigens
not present during tolerization. Tolerance was long lived and not readily reversible in vivo …
disease (GVHD)(1). We describe an ex vivo approach in which the blockade of CD40 ligand
(CD40L: CD154): CD40 interactions, a pathway required for optimal T cell expansion,
induces donor CD4 (+) T cells to become tolerant to host alloantigens (2). High doses of
tolerized cells did not cause GVHD lethality in vivo. T cells had intact responses to antigens
not present during tolerization. Tolerance was long lived and not readily reversible in vivo …
A major goal of the transplant field is to tolerize donor T cells to prevent graft-versus-host disease (GVHD) (1). We describe an ex vivo approach in which the blockade of CD40 ligand (CD40L:CD154):CD40 interactions, a pathway required for optimal T cell expansion, induces donor CD4(+) T cells to become tolerant to host alloantigens (2). High doses of tolerized cells did not cause GVHD lethality in vivo. T cells had intact responses to antigens not present during tolerization. Tolerance was long lived and not readily reversible in vivo. These data have significant implications for the use of tolerization approaches to prevent human GVHD.
The Journal of Clinical Investigation